MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12969-022-00763-x

Медицинская библиотека · Pediatric rheumatology online journal · 2022

Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study.

van Straalen Joeri W, de Roock Sytze, Giancane Gabriella, Consolaro Alessandro, Rygg Marite, Nordal Ellen B, Rubio-Pérez Nadina, Jelusic Marija, De Inocencio Jaime, Vojinovic Jelena, Wulffraat Nico M, Bruijning-Verhagen Patricia C J, Ruperto Nicolino, Swart Joost F, Paediatric Rheumatology International Trials Organisation (PRINTO)

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Etanercept (ETN) and adalimumab (ADA) are considered equally effective biologicals in the treatment of arthritis in juvenile idiopathic arthritis (JIA) but no studies have compared their impact on patient-reported well-being. The objective of this study was to determine whether ETN and ADA have a differential effect on patient-reported well-being in non-systemic JIA using real-world data.

METHODS

Biological-naive patients without a history of uveitis were selected from the international Pharmachild registry. Patients starting ETN were matched to patients starting ADA based on propensity score and outcomes were collected at time of therapy initiation and 3-12 months afterwards. Primary outcome at follow-up was the improvement in Juvenile Arthritis Multidimensional Assessment Report (JAMAR) visual analogue scale (VAS) well-being score from baseline. Secondary outcomes at follow-up were decrease in active joint count, adverse events and uveitis events. Outcomes were analyzed using linear and logistic mixed effects models.

RESULTS

Out of 158 eligible patients, 45 ETN starters and 45 ADA starters could be propensity score matched resulting in similar VAS well-being scores at baseline. At follow-up, the median improvement in VAS well-being was 2 (interquartile range (IQR): 0.0 - 4.0) and scores were significantly better (P = 0.01) for ETN starters (median 0.0, IQR: 0.0 - 1.0) compared to ADA starters (median 1.0, IQR: 0.0 - 3.5). The estimated mean difference in VAS well-being improvement from baseline for ETN versus ADA was 0.89 (95% CI: -0.01 - 1.78; P = 0.06). The estimated mean difference in active joint count decrease was -0.36 (95% CI: -1.02 - 0.30; P = 0.28) and odds ratio for adverse events was 0.48 (95% CI: 0.16 -1.44; P = 0.19). One uveitis event was observed in the ETN group.

CONCLUSIONS

Both ETN and ADA improve well-being in non-systemic JIA. Our data might indicate a trend towards a slightly stronger effect for ETN, but larger studies are needed to confirm this given the lack of statistical significance.

Для цитирования: van Straalen Joeri W, de Roock Sytze, Giancane Gabriella, Consolaro Alessandro, Rygg Marite, Nordal Ellen B, Rubio-Pérez Nadina, Jelusic Marija, De Inocencio Jaime, Vojinovic Jelena, Wulffraat Nico M, Bruijning-Verhagen Patricia C J, Ruperto Nicolino, Swart Joost F, Paediatric Rheumatology International Trials Organisation (PRINTO). Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study.. Pediatric rheumatology online journal. 2022. DOI: 10.1186/s12969-022-00763-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.